Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia by Webster, Lynn R et al.
RESEARCH ARTICLE Open Access
Effect of duration of postherpetic neuralgia on
efficacy analyses in a multicenter, randomized,
controlled study of NGX-4010, an 8% capsaicin
patch evaluated for the treatment of
postherpetic neuralgia
Lynn R Webster
1, Marvin Tark
2, Richard Rauck
3, Jeffrey K Tobias
4, Geertrui F Vanhove
4*
Abstract
Background: Postherpetic neuralgia (PHN) is a painful and difficult to treat complication of acute herpes zoster.
Current treatment options provide only partial relief and are often limited by poor tolerability. We evaluated the
safety and efficacy of a single 60-minute application of NGX-4010, an 8% capsaicin patch, in patients with PHN.
Methods: This multicenter, double-blind, controlled study randomized 155 patients 2:1 to receive either NGX-4010
or a 0.04% capsaicin control patch. Patients were at least 18 years old with PHN for at least 3 months, and an
average Numeric Pain Rating Scale (NPRS) score of 3 to 9. The primary efficacy endpoint was the percentage
change in NPRS score from baseline to weeks 2-8.
Results: The mean percent reduction in “average pain for the past 24 hours” NPRS scores from baseline to weeks
2-8 was greater in the NGX-4010 group (36.5%) compared with control (29.9%) although the difference was not
significant (p = 0.296). PGIC analysis demonstrated that more NGX-4010 recipients considered themselves improved
(much, or very much) compared with control at weeks 8 and 12, but the differences did not reach statistical
significance. Post hoc analyses of patients with PHN for at least 6 months showed significantly greater reductions
in “average pain for the past 24 hours” NPRS scores from baseline to weeks 2-8 in NGX-4010 patients compared to
controls (37.6% versus 23.4%; p = 0.0291). PGIC analysis in this subgroup demonstrated that significantly more
NGX-4010 recipients considered themselves much or very much improved compared with control at week 12 (40%
versus 20%; p = 0.0403;).
Conclusions: Although treatment appeared to be safe and well tolerated, a single 60-minute application of NGX-
4010 failed to show efficacy in this study which included patients with PHN for less than 6 months. Large
reductions in pain observed among control patients with pain for less than 6 months may have been due to
spontaneous resolution of PHN, may have confounded the results of the prespecified analyses, and should be
taken into account when designing PHN studies.
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Postherpetic neuralgia (PHN) is a painful complication
of acute herpes zoster (shingles) that is caused by reacti-
vation of the varicella zoster virus usually contracted in
childhood. Acute herpes zoster is often very painful.
Usually this pain subsides, but if it persists beyond heal-
ing, it is referred to as PHN. Transition from acute
herpes zoster to PHN occurs when the pain in the
affected area persists months after crusting of the skin
lesions. Definitions of PHN vary from as short as
1 month to as long as 6 months after lesion crusting
[1]. The prevalence of PHN increases with age with
between 25% and 50% of adults older than 50 years, and
up to 75% of patients with herpes zoster over 70 years,
developing PHN [2-4].
The treatment of peripheral neuropathic pain syn-
dromes commonly requires the use of more than one
neuropathic pain medication [5-7] such as anticonvul-
sants (pregabalin and gabapentin), topical lidocaine,
opioids, tricyclic antidepressants, and selective serotonin
and norepinephrine reuptake inhibitors (SSNRIs).
Despite the availability of various options, most of these
treatments provide only partial relief [8-11] and their
use can be limited by poor tolerability issues such as
central nervous system side effects, the need for titra-
tion, and administration of multiple daily doses.
Sensitization of peripheral nociceptors that express
transient receptor potential vanilloid 1 receptor
(TRPV1), a ligand-gated non-selective cation channel, is
thought to play a role in PHN [1,12]. Treatment strate-
gies directly targeting TRPV1 have been developed.
Capsaicin is a highly selective activating ligand for
TRPV1, and causes depolarization, action potential
initiation, and the transmission of pain signals resulting
in a burning sensation, hyperalgesia, allodynia, and
erythema. Following continued capsaicin exposure, how-
ever, TRPV1-containing sensory axons become defunc-
tionalized, preventing pain transmission and resulting in
a reduced pain response [13,14]. Low-concentration
capsaicin creams (0.025% and 0.075%) have demon-
strated efficacy in the treatment of PHN [4,15,16]. How-
ever, they require multiple daily applications over
several weeks to achieve significant pain relief and cause
a burning sensation at the application site both of which
may lead to a lack of compliance. NGX-4010 is a high-
concentration capsaicin dermal patch (capsaicin, 8%)
developed to rapidly deliver a therapeutic dose of cap-
saicin locally into the skin. A single 60-minute applica-
tion of NGX-4010 has been shown to reduce pain in
controlled clinical trials in patients with PHN [17-19].
We report the results of a multicenter, double-blind,
controlled, phase 3 study that evaluated the safety and
efficacy of a single application of NGX-4010 in patients
with PHN. In contrast to the other NGX-4010 studies
that only allowed PHN patients to enroll if at least
6 months had elapsed since vesicle crusting, patients in
this study were allowed to enroll if at least 3 months
had elapsed since vesicle crusting
Methods
Patients
Patients 18 years or older with a diagnosis of PHN and
an average Numeric Pain Rating Scale (NPRS) [9] score
o f3t o9( i n c l u s i v e )w e r ee l i g i b l ei fa tl e a s t3m o n t h s
had elapsed since vesicle crusting. Patients taking
chronic pain medications had to be on a stable dose of
those medications for at least 21 days before the day of
s t u d yp a t c ha p p l i c a t i o na n dr e m a i no nas t a b l ed o s e
throughout the study period. It was prespecified that at
least 25% of patients would not be taking concomitant
pain medications at entry. Women of childbearing age
were required to have a negative pregnancy test and be
willing to use an effective method of contraception for
30 days after exposure to study medication.
Exclusion criteria were as follows: use of any topically
applied pain medication on the painful area within 21 days
before the day of application of the study patch; current
use of any investigational drug or class 1 anti-arrhythmic
drug; uncontrolled diabetes mellitus or uncontrolled
hypertension; significant pain of an etiology other than
PHN; painful PHN areas located only on the face, above
the scalp hairline, or near mucous membranes; and hyper-
sensitivity to capsaicin, local anesthetics, oxycodone
hydrochloride, hydrocodone, or adhesives. As prior use of
high-dose opioids could limit the responsiveness to the
optional oral opioid rescue analgesics used during the
treatment procedure, patients using concomitant opioid
medication that were not orally or transdermally adminis-
tered or exceeded a total dose of 60 mg/day morphine
equivalent were excluded.
The study was approved by Institutional Review
Boards at all participating sites, and conducted in accor-
dance with the ethical principles of the Declaration of
Helsinki, Good Clinical Practice guidelines, and applic-
able regulatory requirements. Written informed consent
was obtained from all participating patients before initi-
ating study-related procedures.
Procedures
A baseline screening period was followed by a treatment
day (day 0), a 12-week post-treatment assessment period
with clinic visits at weeks 4, 8, and 12. Eligible patients
were randomized 2:1 to receive either NGX-4010 (cap-
saicin 640 μg/cm
2, 8%, NeurogesX Inc., San Mateo, CA)
or an identically appearing low-concentration capsaicin
control patch (capsaicin 3.2 μg/cm
2,0 . 0 4 % )f o r
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Page 2 of 1160 minutes according to a randomization scheme pre-
pared by Cardinal Health (Morrisville, NC). The low-
concentration capsaicin control patches were used in
place of placebo patches to provide effective blinding in
the study since topical capsaicin can produce local
erythema and a burning sensation. All patients were
pre-treated with a topical anesthetic cream (ELA-Max4®,
lidocaine 4%; Ferndale Laboratories, Inc., Ferndale, MI)
for 60 minutes before the application of the study or
control patch(es) which were applied directly to the
painful area(s) (up to 1000 cm
2). After patch removal,
the area was cleansed with a proprietary cleansing gel
formulated to remove residual capsaicin. Patients were
monitored for 2 hours after patch removal. Local cool-
ing as well as oxycodone hydrochloride oral solution
(1 mg/mL) or equivalent could be administered at the
onset of treatment-associated discomfort and as needed.
Patients could take opioid rescue medication (hydroco-
done bitartrate/acetaminophen 5 mg/500 mg) every
8 hours for up to 3 days after patch application for
treatment-associated discomfort as needed. Topical pain
medications were not permitted during the 12-week
study period. Patients were allowed to take acetamino-
phen up to 2 g/day as needed for aches and pains.
Efficacy Measures and Data Analysis
Efficacy was evaluated with daily Numeric Pain Rating
Scale (NPRS) scores throughout the 12-week study per-
iod. The NPRS is an 11-point scale (0 to 10) with 0
indicating no pain and 10 indicating the worst possible
pain [20]. Patients recorded NPRS scores for “worst
pain for the past 24 hours”, “average pain for the past
24 hours”,a n d“pain now” i nat a k eh o m ed i a r yb e g i n -
ning on the evening of the Treatment Visit (Day 0)
through the evening before the week 12 visit. Patient
Global Impression of Change (PGIC; patients reported
how they felt compared to baseline on a scale of -3 indi-
cating “very much worse” to +3 indicating “very much
improved” with 0 being “no change”) and investigator-
rated Clinical Global Impression of Change (CGIC) [21]
were evaluated at weeks 4, 8 and 12. The modified Brief
Pain Inventory (BPI) [22] was collected at screening and
at weeks 4, 8 and 12. The Short-Form McGill Pain
Questionnaire (SFMPQ) [23] was collected at screening
and at weeks 4, 8 and 12.
The primary efficacy endpoint was the percentage
change in “average pain for the past 24 hours” NPRS
scores from baseline to weeks 2 through 8. To avoid the
potential confounding effect of allowed opioid rescue
medications during days 0 to 3, week 1 NPRS scores
were not included in the primary analysis. Other efficacy
measures included: percenta g ec h a n g ei nN P R Ss c o r e s
from baseline to weeks 2-4 and 2-12; the percentage of
patients with a ≥ 30% and ≥ 50% reduction in NPRS
score from baseline to weeks 2-4, 2-8 and 2-12; the per-
centage of patients considered improved (much, or very
much) on the PGIC and CGIC at weeks 4, 8 and 12;
changes from screening in the BPI questionnaire col-
lected at weeks 4, 8 and 12; and changes from screening
in the SFMPQ questionnaire collected at weeks 4, 8 and
12. Weekly changes in NPRS scores were also performed.
Efficacy analyses were based on the intent-to-treat
population that consisted of all patients who received
any study treatment and had at least 3 days of available
NPRS scores during the baseline period. The NGX-4010
group was compared to the control group using a gen-
der-stratified ANCOVA model with baseline pain as the
only covariate. The same method was used to analyze
the differences between the NGX-4010 groups and the
control group in NPRS scores for weeks 2-4 and 2-12.
Logistic regression with gender and baseline as covari-
ates tested the difference in the proportion of patients
with a ≥30% and a ≥50% mean decrease from baseline
in NPRS scores during weeks 2-4, 2-8 and 2-12. For the
Short-Form McGill Pain Questionnaire and BPI, a t-test
w a su s e dt ot e s tf o rd i f f e r e n c e si nc h a n g ef r o ms c r e e n -
ing to week 8 between treatment groups. For PGIC and
CGIC, Fisher’s exact test was used to test for differences
between treatment groups in the percentage of patients
considered improved (much, or very much). To assess
the potential impact of enrolling patients with disease of
less than 6 months duration, post hoc analyses were
performed on the subgroup of patients with PHN dura-
tion of at least 6 months (180 days). Treatment compar-
isons were performed using gender-stratified ANCOVA
to test for a difference between the NGX-4010 and con-
trol groups, with baseline pain, pre-anesthetic pain
score, and percent change in NPRS score from pre-anes-
thetic to pre-patch application time point as covariates.
The percent change in pain following application of the
topical anesthetic and the pain score reported immedi-
ately before application of the topical anesthetic were
found to be significant covariates in these post hoc ana-
lyses and included in the model.
Missing post-treatment NPRS scores were imputed
using a modified last-observation-carried-forward
approach. If the NPRS score was missing on days 0-8, the
baseline score was imputed for that day. If the NPRS
score was missing for any day past day 8, then the latest
available non-missing score collected before that day was
imputed for that missing value. If NPRS scores were
missing for all post treatment study days (including day
0), then the baseline score was imputed for all missing
scores. No imputation was used for the calculation of
weekly scores. For the calculation of NPRS baseline
scores, all available screening scores which were not
biased by pain medication changes were used. For
changes in non-SSRI antidepressant or anticonvulsant
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Page 3 of 11medications, pain scores up to 14 days after the medica-
tion change were considered biased. For changes in other
pain medications, pain scores up to the day of medication
change were considered biased. Changes in minor OTC
analgesics (acetaminophen, aspirin) were ignored.
It was estimated that to achieve 90% power at the 0.05
significance level, a total of 150 patients, with 100 desig-
nated for NGX-4010 and 50 designated for control
treatment, were required to detect a difference of 15%
in change from baseline in NPRS scores between the
NGX-4010 and control group.
Safety Measures and Data Analysis
Safety was assessed by continuous monitoring of adverse
events and periodic assessments of clinical laboratory
parameters, vital signs, physical examinations, dermal
assessments (0- to 7-point severity score) [24], pain
experienced during and after the patch application by
using NPRS scores on the day of treatment (prior to topi-
cal local anesthetic application, 5 minutes prior to patch
application, 5 minutes prior to patch removal and 1 hour
after patch removal), and rescue medication and conco-
mitant medication usage. Treatment associated erythema,
discomfort and pain on the day of treatment were not
captured as adverse events but reported as dermal assess-
ment scores or “Pain Now” NPRS scores. Standardized
neurosensory examinations (allodynia, light brush, pin-
prick, warmth and vibration) were performed at screen-
ing, week 4, week 8 and 12. Changes in neurosensory
assessments from screening to each assessment time
point were categorized using prespecified algorithms. On
the day of treatment, the proportions of patients report-
ing each level of dermal response, the “Pain Now” NPRS
score and the change in “Pain Now” NPRS score from
the pre-local anesthetic time point, vital signs (systolic
blood pressure, diastolic blood pressure, heart rate, and
respiratory rate), change in vital signs from the pre-local
anesthetic time point and the number and proportion of
patients who had shorter patch application times (< 90%
of intended patch application duration) were summar-
ized. The proportion of patients classified as “same or no
increase”, “ < 33% increase”,o r“ > 33% increase” in maxi-
mum pain score from baseline during the first 48 hours
were also summarized.
Adverse events were coded using the Medical Diction-
ary for Regulatory Activities (MedDRA; Version 7.0).
Rescue medication use from days 0 to 5, the number of
patients completing the intended patch duration, demo-
graphics, and baseline clinical characteristics were com-
pared between groups with Fisher exact tests or t-tests,
as appropriate. The proportions of patients reporting
each level of maximum dermal response on the day of
treatment were compared between the active group and
the control group using Fisher’s exact test. The results
of the allodynia assessments at each visit were compared
using a t-test while the rest of the neurologic sensory
exams were compared using a Cochran-Mantel-Haens-
zel test for trend.
Results
Patients
A total of 155 patients were enrolled into the study and
received double-blind treatment: 102 patients received
NGX-4010 and 53 patients received control (Figure 1).
A total of 134 (86%) patients completed the 12-week
study: 91 (89%) patients in the NGX-4010 group and 43
(81%) patients in the control group. The most common
reasons for premature termination included unsatisfac-
tory therapeutic response (NGX-4010: n = 3; Control:
n = 7) and lost to follow-up (NGX-4010: n = 5; Control:
n = 0). No patients terminated the study early due to
adverse events and no patients died during the study.
Demographics, baseline pain scores, duration of PHN,
the size of the painful area, the size of the treated area,
and use of baseline concomitant pain medications
(opioids, antidepressants, anticonvulsants and other)
were similar between treatment groups (Table 1).
Efficacy
Patients treated with a single 60-minute application of
NGX-4010 reported a mean 36.5% reduction in pain
during weeks 2 to 8 compared with 29.9% in the control
group (p = 0.296; Table 2). Forty-nine percent of NGX-
4010 patients were considered to have responded to
treatment (i.e., experienced a ≥ 30% mean decrease from
baseline in pain) during weeks 2 to 8 compared with
45% of controls (p = 0.574). The proportion of patients
who achieved a ≥ 50% decrease in pain scores from
n = 102 
NGX-4010 
n = 91 
Completed 
Study 
N = 155 
Patients Receiving Double-Blind Treatment 
n = 53 
Control 
n = 11 
Withdrawn 
n = 43 
Completed 
Study 
n = 10 
Withdrawn
Unsatisfactory 
Therapeutic Response (3) 
Lost to Follow-up (5) 
Other 
Unsatisfactory 
Therapeutic Response (7) 
Noncompliance (2) 
Other  (3) (1)
Figure 1 Study randomization and disposition.
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Page 4 of 11baseline to weeks 2 to 8 was similar between the treat-
ment groups (36%). Similar results were observed during
weeks 2 to 12. The results of the analyses for change in
“w o r s tp a i nf o rt h ep a s t2 4h o u r s ” and “pain now”
scores from baseline to weeks 2-8 and 2-12 were com-
parable to the results for change in “average pain for the
past 24 hours”.
During week 1, patients receiving NGX-4010 experi-
enced a 36.0% reduction in 24 hour average pain scores
compared to baseline (Figure 2). The observed pain
reduction remained relatively constant over the entire
12 week study period. The mean percent change from
baseline in 24 hour average pain scores was approxi-
mately 5%-10% greater in the NGX-4010 group relative
to the control group at weeks 1 through 8. Differences
between the groups diminished over time, largely due to
continued improvement in the control group.
Although more NGX-4010 recipients considered
themselves to have much, or very much improved com-
pared with controls at weeks 8 and 12, the differences
did not reach statistical significance (Table 2). The
results of the CGIC were comparable to the results of
the PGIC. More NGX-4010 patients were judged by the
study investigators to have been much or very much
improved compared to control patients at week 4 (46%
vs. 37%), week 8 (51% vs. 40%) and week 12 (46% vs.
32%) but the differences were not statistically significant.
Other patient-rated questionnaires (BPI and SFMPQ)
showed no significant differences between the NGX-
4010 and control group.
To assess the potential impact of enrolling patients
with disease of less than 6 months duration, post hoc
analyses were performed on the subgroup of patients
with PHN duration of at least 6 months (180 days). Six-
teen (16%) patients enrolled in the NGX-4010 group
and 10 (18%) patients in the control group had PHN
duration between 3 and 6 months and were excluded
form these analyses. A summary of the “average pain for
the past 24 hours” NPRS scores for weeks 2-8 and 2-12
as well as the results of the responder and PGIC ana-
lyses for this subgroup are presented in Table 3. Demo-
graphics, baseline pain scores, duration of PHN, the size
of the painful area, the size of the treated area, and use
of baseline concomitant pain medications were similar
between treatment groups in this subset of patients.
Patients with PHN for at least 6 months receiving
NGX-4010 had a mean percent change from baseline
during weeks 2 to 8 of -37.6% compared to -23.4% in
controls (p = 0.0291). A greater proportion of NGX-
4010 patients (49%) were considered to have responded
to treatment (i.e., experienced a ≥ 30% mean decrease
from baseline in pain) during weeks 2 to 8 compared
with 40% of controls (P = 0.090). Results for this sub-
group were similar to the results from the subgroup
with PHN duration of less than 6 months with regard to
patients treated with NGX-4010 who showed a mean
Table 1 Patient demographics and clinical characteristics
NGX-4010
(n = 102)
Control
(n = 53)
Demographics
Age (yr), mean ± SD 68.7 ± 12.00 71.2 ± 11.26
Male, n (%) 47 (46%) 25 (47%)
Race
White 89 (87%) 45 (85%)
Black or African American 6 (6%) 3 (6%)
Asian 1 (1%) 1 (2%)
American Indian or Alaska Native 0 (0%) 1 (2%)
Native Hawaiian or Other Pacific Islander 0 (0%) 0 (0%)
Other 6 (6%) 3 (6%)
Clinical characteristics
Duration of Pain (yr), mean ± SD 2.7 ± 2.92 3.4 ± 4.00
Baseline
a “Average Pain for the Past 24 Hours”, mean ± SD 5.4 ± 1.58 5.3 ± 1.53
On Concomitant Pain Medication
b, n (%) 78 (76%) 42 (79%)
Opioids 26 (25%) 13 (25%)
Anticonvulsants 26 (25%) 18 (34%)
Antidepressants 10 (10%) 6 (11%)
Other 52 (51%) 30 (57%)
Size of Painful Area at Screening (cm
2), mean ± SD 337.9 ± 226.46 334.2 ± 221.92
Baseline pain level was defined as the mean of all available non-biased Screening NPRS scores in that category.
A patient was defined as being on concomitant pain medication if pain medication started prior to day of treatment, continued on the day of treatment, and
was taken for at least 7 days.
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Page 5 of 11percent change from baseline during weeks 2 to 8 of
-36.8% (data not shown); however, control patients with
PHN duration of 6 months or more had a smaller mean
percent change from baseline during weeks 2 to 8 com-
pared to control patients in the subgroup with PHN
duration of less than 6 months (-23.4% versus -47.1%,
respectively).
Analysis of PGIC in the subgroup of patients with
PHN for 6 months or longer demonstrated that signifi-
cantly more NGX-4010 recipients considered themselves
to have much or very much improved compared with
the control group at week 12 (40% vs. 20%; p = 0.0403;
Table 3). The results of the CGIC were comparable to
the results of the PGIC. More NGX-4010 patients were
judged by the study investigators to have been much or
very much improved compared to control patients at
w e e k4( 4 2 %v s .3 5 % ) ,w e e k8( 4 9 %v s .3 5 % )a n dw e e k
12 (43% vs. 24%) but the differences were statistically
significant only at week 12 (p = 0.0485). Analyses of
other patient-rated questionnaires in this subgroup (BPI
and SFMPQ) showed no significant differences between
the NGX-4010 and control group.
Safety
NGX-4010 was well tolerated in the majority of patients.
All but 4 of 102 patients (96%) in the NGX-4010 group
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Figure 2 P e r c e n tc h a n g ef r o mb a s e l i n ei n“average pain for
the past 24 Hours” NPRS scores by week. Values shown are
mean and standard error of the mean (SEM). NGX-4010 showed
greater improvement in pain scores at weeks 1 through 8 but the
differences between the two groups diminished over time largely
due to continued improvement in the control group.
Table 2 Clinical efficacy of NGX-4010 in all patients with PHN
NPRS Scores NGX-4010
(n = 102)
Control
(n = 53)
P-value
Baseline, LS mean (SE) 5.4 (0.16) 5.3 (0.22)
95% CI 5.12, 5.73 4.87, 5.72
Change, mean (SE)
Baseline to weeks 2 to 8 -1.8 (0.20) -1.6 (0.27) 0.462
95% CI -2.23, -1.45 -2.13, -1.05
Baseline to weeks 2 to 12 -1.8 (0.20) -1.7 (0.28) 0.750
95% CI -2.25, -1.45 -2.29, -1.18
Percent Change, mean (SE)
Baseline to weeks 2 to 8 -36.5 (3.68) -29.9 (5.10) 0.296
95% CI -43.72, -29.19 -39.94, -19.78
Baseline to weeks 2 to 12 -36.6 (3.75) -32.3 (5.21) 0.509
95% CI -44.02, -29.19 -42.63, -22.05
Patients with ≥ 30% reduction, %
Baseline to weeks 2 to 8 49 45 0.574
Baseline to weeks 2 to 12 49 49 0.956
Patients with ≥ 50% reduction, %
Baseline to weeks 2 to 8 36 36 0.930
Baseline to weeks 2 to 12 39 36 0.628
PGIC
Improved (very much, much)
Week 4, n 100 49
N (%) 40 (40) 19 (39) 1.0000
Week 8, n 91 43
N (%) 43 (47) 14 (33) 0.1351
Week 12, n 95 50
N (%) 41 (43) 15 (30) 0.1518
Webster et al. BMC Neurology 2010, 10:92
http://www.biomedcentral.com/1471-2377/10/92
Page 6 of 11completed at least 90% of the intended patch application
duration. Those patients that did not complete the
intended patch application duration had the patches
removed early due to application site pain or burning.
All patients in the control group completed at least 90%
of the intended patch application duration. On the day
of treatment, mean “Pain Now” NPRS scores decreased
following topical anesthetic and increased following
patch application in both treatment groups (Figure 3).
Patients receiving NGX-4010 reported a mean maxi-
mum increase of 1.9 from the pre-anesthetic time point
during and after patch application. In contrast, though
control patch application resulted in an increase in
NPRS scores, NPRS scores did not increase above pre-
procedure levels. After patch removal, NPRS scores in
the NGX-4010 group decreased to below pre-procedure
levels at 85 minutes after patch removal. During the
first 48 hours, a ≥ 33% increase from baseline in NPRS
score after patch application was reported in 73% of
patients treated with NGX-4010 and 51% of controls.
On the evening of the day of treatment, all treatment
groups had reductions in “pain now” scores compared
to baseline though the reductions were smaller in the
NGX-4010 group (-1.6, -28.0%) compared to control
(-2.3, -34.9%).
Treatment-related pain was manageable in most
patients with the use of local cooling or short-acting
oral opioids. Thirty-four percent of NGX-4010 patients
and 9% of control patients received oxycodone on the
day of treatment. The mean dose of oxycodone used
was 10.6 ± 5.43 (SD) mg for patients treated with NGX-
4010 and 5.6 ± 1.34 (SD) mg for patients treated with
control (p = 0.0010). Few patients used hydrocodone/
acetaminophen for treatment-related pain from days 0-
5: 12% of NGX-4010 patients and 2% of controls.
A total of 76 NGX-4010 patients (75%) and 28 (53%)
control patients reported adverse events. The most fre-
quently reported adverse events were related to local
application site reactions (pruritus, dryness and swel-
ling). These application site reactions occurred more
commonly in NGX-4010 patients (Table 4), were mostly
mild or moderate in severity and transient. Treatment
associated erythema, discomfort and pain on the day of
treatment were not captured as adverse events but
reported as dermal assessment scores or NPRS scores.
Serious adverse events occurred in 7% and 0% of
Table 3 Clinical efficacy of NGX-4010 in patients with PHN duration ≥ 6 months (180 days)
NPRS Scores NGX-4010
(n = 86)
Control
(n = 43)
P-value
Baseline, LS mean (SE) 5.4 (0.17) 5.2 (0.24)
95% CI 5.05, 5.72 4.77, 5.72
Change, mean (SE)
Baseline to weeks 2 to 8 -1.8 (0.20) -1.4 (0.29) 0.072
95% CI -2.18, -1.38 -1.92, -0.79
Baseline to weeks 2 to 12 -1.8 (0.20) -1.3 (0.28) 0.160
95% CI -2.23, -1.44 -1.90, -0.78
Percent Change, mean (SE)
Baseline to weeks 2 to 8 -37.6 (3.66) -23.4 (5.21) 0.0291
95% CI -44.85, -30.35 -33.74, -13.10
Baseline to weeks 2 to 12 -37.5 (3.76) -25.5 (5.35) 0.069
95% CI -44.98, -30.10 -36.06, -14.88
Patients with ≥ 30% reduction, %
Baseline to weeks 2 to 8 49 40 0.090
Baseline to weeks 2 to 12 50 44 0.277
Patients with ≥ 50% reduction, %
Baseline to weeks 2 to 8 35 30 0.270
Baseline to weeks 2 to 12 40 28 0.065
PGIC
Improved (very much, much)
Week 4, n 84 40
N (%) 31 (37) 14 (35) 1.0000
Week 8, n 78 35
N (%) 34 (44) 10 (29) 0.1487
Week 12, n 81 41
N (%) 32 (40) 8 (20) 0.0403
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Page 7 of 11NGX-4010 and control patients, respectively. These
events consisted of atrial fibrillation, cardiac valve dis-
ease, myocardial infarction, tachycardia, diarrhea, food
poisoning, nausea, vomiting, cholelithiasis, viral gastro-
enteritis, rib fracture, arthritis, malignant lung neoplasm,
pneumothorax and orthostatic hypertension. Only one
(myocardial infarction) occurred in more than 1 patient
(in two). No serious adverse event was considered
related to treatment.
Dermal irritation was generally mild and transient. At
patch removal, 83% of NGX-4010 patients and 62% of
control patients had dermal scores of two or more (defi-
nite erythema or minimal edema or minimal papular
response). Two hours after patch removal, 52% of NGX-
4010 patients had dermal scores of 2 or more compared
to 4% of controls. Few NGX-4010 patients (< 3%) had a
d e r m a la s s e s s m e n ta b o v e2a ta n yt i m ep o i n t .B yw e e k
4, the majority of patients in the both the NGX-4010
(92%) and control (89%) groups had no evidence of der-
mal irritation (score = 0) and no patients in either the
NGX-4010 or control groups had dermal assessment
scores ≥ 2.
There were no statistically significant differences
between the treatment groups in light brush, pinprick,
vibration, and warmth sensations at screening, week 4,
week 8, or week 12. No trends consistent with a
decrease in sensory function were observed in either
group over the 12-week study period. Though patients
treated with NGX-4010 demonstrated a larger reduction
in mean surface area of allodynia from screening to
week 8 (-43.4 cm
2) compared to control (-25.1 cm
2), the
results were highly variable and not statistically signifi-
cantly different.
Small, transient changes in blood pressure were noted
during and shortly after the treatment procedure. Blood
pressure decreased following topical anesthetic applica-
tion and increased after patch application in the NGX-
4010 group, while blood pressure remained at or below
the pre-treatment level during patch treatment through
2 hours post-treatment in the control group. These
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Figure 3 Change in “Pain Now” NPRS scores from pre-anesthetic time point during the treatment procedure. Values shown are mean
and SEM. “Pain Now” NPRS scores decreased following topical anesthetic and increased following patch application in both treatment groups.
Patients receiving NGX-4010 reported a mean maximum increase of 1.9 from the pre-anesthetic time point. NPRS scores did not increase above
pre-procedure levels in those receiving control. NPRS scores in the NGX-4010 group decreased to below pre-procedure levels at 85 minutes after
patch removal.
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Page 8 of 11changes paralleled increases in pain as measured by
NPRS scores during this period. For the NGX-4010
group, mean increases were ≤ 7.9 mm Hg in systolic
blood pressure and ≤ 3.3 mm Hg in diastolic blood
pressure. Blood pressure began returning toward pre-
treatment values within 60 minutes after patch removal.
One subject treated with NGX-4010 experienced an
adverse event of increased blood pressure on the day of
treatment that was not considered related to treatment.
There was no evidence of an effect of NGX-4010 on
any laboratory parameter evaluated. Hematologic and
serum chemistry laboratory values showed no trends for
any parameter during the 12-week study in either treat-
ment group. No other safety concerns were identified.
Discussion
This randomized, double-blind, controlled study in
patients with PHN for at least three months shows that
following treatment with NGX-4010, pain scores began
declining as early as the evening of the day of treatment
and were reduced by approximately 36% during week 1.
The pain reduction remained relatively constant over
t h eo v e rt h ee n t i r e1 2w e e ks t u d yp e r i o d .W h i l ep a i n
reduction in the NGX-4010 group was 5-10% higher
than the control group during the first 8 weeks, differ-
ences between the groups diminished over time; this
was largely due to continued improvement in the con-
trol group. Spontaneous improvement of PHN is often
observed, primarily during the first 6 months after onset
of the disease [25]. Since this study required patients
with only 3 months after vesicle crusting and other stu-
dies of NGX-4010 conducted in PHN required 6
months post vesicle crusting [17-19], exploratory post
hoc analyses of patients with PHN for 6 months or
more, a population that would be less likely to experi-
ence spontaneous improvement, were also performed.
Table 4 Most frequently (≥3% of patients) reported adverse events
System Organ Class
Preferred Term, n (%)
NGX-4010
(n = 102)
Control
(n = 53)
Number of Patients Reporting 1 or More Adverse Events 76 (75%) 28 (53%)
Gastrointestinal Disorders 10 (10%) 4 (8%)
Nausea 5 (5%) 1 (2%)
General Disorders and Administration Site Conditions 38 (37%) 12 (23%)
Application Site Burning 3 (3%) 0
Application Site Discoloration 0 3 (6%)
Application Site Dryness 10 (10%) 2 (4%)
Application Site Erythema 4 (4%) 0
Application Site Pain 4 (4%) 2 (4%)
Application Site Papules 4 (4%) 2 (4%)
Application Site Pruritus 17 (17%) 6 (11%)
Application Site Swelling 10 (10%) 1 (2%)
Application Site Urticaria 3 (3%) 0
Application Site Vesicles 5 (5%) 1 (2%)
Pain Exacerbated 3 (3%) 0
Infections and Infestations 16 (16%) 8 (15%)
Bronchitis 3 (3%) 0
Herpes Zoster 3 (3%) 2 (4%)
Upper Respiratory Tract Infection 1 (1%) 2 (4%)
Injury, Poisoning and Procedural Complications 4 (4%) 6 (11%)
Injury 1 (1%) 2 (4%)
Musculoskeletal and Connective Tissue Disorders 10 (10%) 2 (4%)
Back Pain 3 (3%) 1 (2%)
Nervous Systems Disorders 5 (5%) 5 (9%)
Dizziness 1 (1%) 3 (6%)
Respiratory, Thoracic and Mediastinal Disorders 12 (12%) 4 (8%)
Cough 3 (3%) 0
Nasal Congestion 1 (1%) 2 (4%)
Nasopharyngitis 3 (3%) 2 (4%)
Vascular Disorders 5 (5%) 1 (2%)
Hypertension 3 (3%) 0
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Page 9 of 11A significantly greater reduction in pain was observed in
patients treated with NGX-4010 compared to control
for weeks 2-8 in this subgroup. The response in control
patients with PHN for 6 months or more was lower
than that observed in the cohort with PHN for less than
6 months while the response in patients treated with
NGX-4010 was similar to that observed in the cohort
with PHN for less than 6 months. Given these findings,
it is possible that spontaneous improvement in those
patients with PHN of less than 6 months duration con-
founded the overall study results. Studies of NGX-4010
that required patients to have PHN for at least 6
months have demonstrated that a single application of
NGX-4010 can provide pain relief that can be main-
tained for up to 12 weeks following treatment [17-19].
Overall, these findings suggest that, to reduce the poten-
tial confounding effect of spontaneous resolution, PHN
studies should consider limiting enrollment to patients
with PHN for at least 6 months duration.
Another possible factor confounding the results of this
study is the use of a low-concentration capsaicin control
patch instead of an inert placebo. A patch containing a
low-concentration of capsaicin was chosen as a control
to address the difficulty in blinding the use of topical
capsaicin. The low-concentration patch delivered an
amount of capsaicin that, like NGX-4010, was capable
of producing local application site reactions. Erythema,
pain, and rescue medication usage occurred with both
capsaicin formulations suggesting that the blind could
not be broken based on an individual patient’si n i t i a l
reaction to treatment. The use of a low-concentration
capsaicin control patch may have led to an underestima-
tion of the efficacy of NGX-4010 either because of a
possible intrinsic analgesic effect of the low-concentra-
tion capsaicin control patch or because of an enhanced
placebo response due to application site reactions that
resulted from the capsaicin in the control.
Lastly, power estimations for this study were calcu-
lated using a 15% difference between the treatment
groups. This estimate was based on the results of the
first randomized, controlled NGX-4010 study in PHN
patients which showed a small pain reduction in the
control arm (-4.4%) and a 28% difference in NPRS score
reduction between NGX-4010 and control during weeks
2-4 [17]. Subsequent studies, however, have shown
much larger reductions in the control arms and treat-
ment differences that were less than those observed in
the first study [18,19]. Therefore, the sample size in this
study was not large enough to show a significant differ-
ence between the two treatment groups.
Treatment with NGX-4010 was well tolerated in the
majority of patients, with nearly all patients completing
the full duration of treatment. Although an initial
increase in pain was evident during and after NGX-4010
patch application, pain returned to near pre-procedure
levels within 85 minutes after patch removal and by the
evening of the day of treatment, patients had on average
less pain compared with baseline. Mild, transient dermal
irritation was observed in a majority of patients after
patch removal. Capsaicin-related local application site
reactions were the most common adverse events and
were transient, mostly mild to moderate, and self-lim-
ited. Application site pain could be adequately managed
by pre-treatment with a local anesthetic and local cool-
ing or, if needed, short-acting oral opioid analgesics.
Small transient increases in systolic and diastolic blood
pressure seen during or shortly after treatment were
likely due to treatment-associated discomfort.
No reduction in sensory function following NGX-4010
administration was observed suggesting that capsaicin
treatment can lead to pain reduction without clinically
relevant changes in protective sensation. Indeed, when
used as a topical analgesic, capsaicin’s mechanism of
action involves the selective and reversible defunctionali-
zation of cutaneous sensory nerve endings expressing
TRPV1, which have been shown to be hyperactive in
painful peripheral neuropathies. The high selectivity of
capsaicin for the TRPV1 receptor, coupled with the
selective expression of TRPV1 in nociceptive sensory
nerves, suggests that even with defunctionalization of
cutaneous nociceptors, other skin sensory nerve endings
that are capsaicin-insensitive, including those that arise
from Ab-fibers that transduce tactile and proprioceptive
stimuli, will be intact and functional [13,26]. In addition,
only a subpopulation of Aδ-fibers expresses TRPV1 and
at least 6 other TRP channels (TRPV2, TRPV3, TRPV4,
TRPM2, TRPM4, and TRPM5) participate in hot/warm
thermal perception [26,27].
Conclusion
Although treatment appeared to be safe and well toler-
ated, a single application of NGX-4010 failed to show
efficacy in this study which included patients with PHN
for less than 6 months. Spontaneous resolution of PHN,
which is primarily observed during the first 6 months,
may have confounded the results. Therefore, when
designing PHN studies, the potential for spontaneous
resolution should be taken into account.
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